Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
**Background:** Despite advances in tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia in chronic phase (CML-CP), a sizeable proportion of patients with CML-CP remains refractory or intolerant to these agents. **Objectives:** Treatment patterns, healthcare resource utilization (HR...
Saved in:
Main Authors: | Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Q. Wu, Pallavi Patwardhan |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2022-08-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.36975 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective
by: Ehab L. Atallah, et al.
Published: (2022-08-01) -
Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
by: Prateek Sharma, et al.
Published: (2023-03-01) -
Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models
by: Pallavi Sontakke, et al.
Published: (2016-01-01) -
Acute Myeloid Leukemia Presenting as Myeloid Sarcoma with a Predisposition to the Gynecologic Tract
by: Ryan M. Kahn, et al.
Published: (2019-01-01) -
Acute Myeloid Leukemia Presenting with Pulmonary Tuberculosis
by: Merlin Thomas, et al.
Published: (2014-01-01)